Loading…
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $19M | $-76M | $-77M | $-43M | -37.0% | 70.9% | - |
| 2024 | $11M | $-13M | $-25M | $-23M | 41.1% | 11.6% | - |
| 2023 | $10M | $-6M | $-6M | $56M | 9.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Revenue | 9.76 | 10.90 | 18.62 |
| Operating Expense | 16.15 | 24.11 | 95.43 |
| Operating Income | -6.39 | -13.22 | -76.81 |
| EBITDA | -6.25 | -13.05 | -76.49 |
| EBIT | -6.39 | -13.22 | -76.81 |
| Pretax Income | -6.38 | -13.22 | -76.83 |
| Tax Provision | 0 | 11.91 | -0.14 |
| Net Income | -6.38 | -25.12 | -76.68 |
| Net Income Common Stockholders | -6.38 | -25.12 | -76.68 |
| Total Expenses | 16.15 | 24.11 | 95.43 |
| Research And Development | 12.65 | 19.20 | 53.76 |
| Selling General And Administration | 3.50 | 4.92 | 41.68 |
| Normalized EBITDA | -6.25 | -13.05 | -76.49 |
| Normalized Income | -6.38 | -25.12 | -76.68 |
| Basic EPS | -0.37 | -1.47 | -4.48 |
| Diluted EPS | -0.37 | -1.47 | -4.48 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0.21 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -6.38 | -25.12 | -76.68 |
| Reconciled Depreciation | 0.14 | 0.17 | 0.32 |
| Net Income From Continuing And Discontinued Operation | -6.38 | -25.12 | -76.68 |
| Total Operating Income As Reported | -6.39 | -13.22 | -76.81 |
| Diluted Average Shares | 17.12 | 17.12 | 17.11 |
| Basic Average Shares | 17.11 | 17.11 | 17.11 |
| Diluted NI Availto Com Stockholders | -6.38 | -25.12 | -76.68 |
| Net Income Including Noncontrolling Interests | -6.38 | -25.12 | -76.68 |
| Net Income Continuous Operations | -6.38 | -25.12 | -76.68 |
| Other Income Expense | 0 | 0 | -0.01 |
| Other Non Operating Income Expenses | 0 | 0 | -0.01 |
| General And Administrative Expense | 3.50 | 4.92 | 41.68 |
| Other Gand A | 3.50 | 4.92 | 41.68 |
| Operating Revenue | 9.76 | 10.90 | 18.62 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Atrium Therapeutics, Inc.this co. | RNA | $202M | - | -3.21 | -37.0% | - |
| LifeMD, Inc. | LFMD | $210M | - | 8.93 | 62.0% | -27.13 |
| Electromed, Inc. | ELMD | $208M | 24.37 | 4.57 | 17.4% | 15.06 |
| Utah Medical Products, Inc. | UTMD | $207M | 19.24 | 1.74 | 9.5% | 7.91 |
| OraSure Technologies, Inc. | OSUR | $205M | - |
| 0.61 |
| -20.2% |
| -0.32 |
| OmniAb, Inc. | OABI | $197M | - | 0.74 | -24.3% | -3.48 |
| Replimune Group, Inc. | REPL | $197M | - | 0.90 | -59.5% | -0.01 |
| Lucid Diagnostics Inc. | LUCD | $194M | - | -3.11 | -530.4% | -4.51 |
| Nkarta, Inc. | NKTX | $192M | - | 0.61 | -33.3% | 0.08 |
| Peer Median | - | 21.80 | 0.82 | -22.2% | -0.17 | |